215 related articles for article (PubMed ID: 24461997)
1. Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis.
Guo Y; Shi M; Shen X; Yang C; Yang L; Zhang J
Clin Colorectal Cancer; 2014 Jun; 13(2):110-8. PubMed ID: 24461997
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
Skof E; Rebersek M; Hlebanja Z; Ocvirk J
BMC Cancer; 2009 Apr; 9():120. PubMed ID: 19386096
[TBL] [Abstract][Full Text] [Related]
4. Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
Montagnani F; Chiriatti A; Licitra S; Aliberti C; Fiorentini G
Clin Colorectal Cancer; 2010 Oct; 9(4):243-7. PubMed ID: 20920997
[TBL] [Abstract][Full Text] [Related]
5. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
6. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
Uygun K; Bilici A; Kaya S; Oven Ustaalioglu BB; Yildiz R; Temiz S; Seker M; Aksu G; Cabuk D; Gumus M
Asian Pac J Cancer Prev; 2013; 14(4):2283-8. PubMed ID: 23725128
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI).
Ding HH; Wu WD; Jiang T; Cao J; Ji ZY; Jin JH; Wang JJ; Song WF; Wang LW
Tumour Biol; 2015 May; 36(5):3361-9. PubMed ID: 25534239
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
Ocvirk J; Rebersek M; Boc M
Anticancer Res; 2011 May; 31(5):1777-82. PubMed ID: 21617239
[TBL] [Abstract][Full Text] [Related]
9. A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer.
Lim SH; Kim TW; Hong YS; Han SW; Lee KH; Kang HJ; Hwang IG; Lee JY; Kim HS; Kim ST; Lee J; Park JO; Park SH; Park YS; Lim HY; Jung SH; Kang WK
Br J Cancer; 2015 Nov; 113(10):1421-6. PubMed ID: 26505681
[TBL] [Abstract][Full Text] [Related]
10. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
Jackson NA; Barrueco J; Soufi-Mahjoubi R; Marshall J; Mitchell E; Zhang X; Meyerhardt J
Cancer; 2009 Jun; 115(12):2617-29. PubMed ID: 19382200
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
Patt YZ; Lee FC; Liebmann JE; Diamandidis D; Eckhardt SG; Javle M; Justice GR; Keiser W; Salvatore JR; Bexon A; Lin E
Am J Clin Oncol; 2007 Aug; 30(4):350-7. PubMed ID: 17762434
[TBL] [Abstract][Full Text] [Related]
12. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J
J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
Moosmann N; Heinemann V
Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
17. Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab.
Kotaka M; Xu R; Muro K; Park YS; Morita S; Iwasa S; Uetake H; Nishina T; Nozawa H; Matsumoto H; Yamazaki K; Han SW; Wang W; Ahn JB; Deng Y; Cho SH; Ba Y; Lee KW; Zhang T; Satoh T; Buyse ME; Ryoo BY; Shen L; Sakamoto J; Kim TW
Chin J Cancer; 2016 Dec; 35(1):102. PubMed ID: 28007025
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
Shigeta K; Hasegawa H; Okabayashi K; Tsuruta M; Ishii Y; Endo T; Ochiai H; Kondo T; Kitagawa Y
Int J Cancer; 2016 Aug; 139(4):946-54. PubMed ID: 27061810
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry.
Kocakova I; Melichar B; Kocak I; Bortlicek Z; Büchler T; Dusek L; Petruzelka L; Kohoutek M; Prausová J; Finek J; Mohelnikova-Duchonova B; Vyzula R
Anticancer Res; 2015 Jun; 35(6):3455-61. PubMed ID: 26026110
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
García Alfonso P; Muñoz Martin A; Alvarez Suarez S; Blanco Codeidido M; Mondejar Solis R; Tapia Rico G; López Martín P; Martin M
Onkologie; 2013; 36(6):363-7. PubMed ID: 23774151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
